# Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

> **NCT04982354** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Guenther Koehne**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** CPX-351
- **DRUG:** Midostaurin
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **DRUG:** Fludarabine
- **BIOLOGICAL:** CD34+ selected allogeneic stem cell transplant from an HLA-compatible donor

## Key facts

- **NCT ID:** NCT04982354
- **Lead sponsor:** Guenther Koehne
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-07-05
- **Primary completion:** 2031-08-01
- **Final completion:** 2032-08-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Could not accrue
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04982354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04982354, "Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04982354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*